NCI federally funded research and development center (ffrdc) contract
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N91019D00024
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 185 $6,803,449,351 obligated
Award facts
- Opportunity
-
- N02CO7240681 Solicitation number
- The National Cancer Institute's Federally Funded Research and Development Center (FFRDC) Frederick National Laboratory for Cancer Research (FNLCR) Award Notice · Posted Mar 1, 2016
- Combined order value
-
- $6,937,961,021 Current, with exercised options
- $7,126,473,169 Potential, with all options
- Last date to order 98% complete
- IDV ceiling 62% used
- $10,916,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded an indefinite-delivery contract to Leidos Biomedical Research Inc. on June 26, 2019, with a ceiling value of $10.916 billion. This is a single-award FFRDC contract with no set-aside.
Place of performance is Frederick, Maryland at the Frederick National Laboratory for Cancer Research, with work extending to subordinate NIH institutes and collaborative sites.
The contract supports comprehensive biomedical research execution, facilities infrastructure management, clinical trial support, and specialized manufacturing spanning monoclonal antibodies, gene therapy vectors, vaccine platform development, and chemistry, manufacturing, and controls development of therapeutic candidates. The contract runs through December 26, 2026.
Leidos Biomedical Research, a subsidiary of Leidos Holdings Inc., operates the Frederick National Laboratory as NCI's FFRDC contractor. Recent task-order activity issued under this IDIQ reflects sustained operational and research support across NCI's mission. Notable recent orders include an $837.7 million NCI operational task order (August 31, 2025, completion August 30, 2027) covering research and operational services across multiple scientific domains; a $28.53 million FFRDC lease arrangement (August 31, 2025, completion August 30, 2026); a $15.99 million facilities requirements order (September 15, 2025, completion September 13, 2030); a $10.1 million elevator refurbishment project (September 30, 2025, completion September 27, 2030); and multiple smaller facilities infrastructure orders totaling millions in campus improvements including roof replacements, chiller replacements, fire suppression systems, stair replacements, and switchboard upgrades. Recent research-focused orders span CPTAC biospecimen acquisition and processing, proteomic and antibody production, manufacturing process development, and drug product formulation and stability studies. The contractor maintains a stable workforce of approximately 1,830 FTEs and engages specialized subcontractors including Abbott Molecular Inc., Tecan U.S. Inc., Bio-Rad Laboratories, and academic partners such as Stanford University and the University of Pittsburgh for research activities.
Task orders
Show 40 more
Latest 50 of 185 listed here. See the rest on GovTribe.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | -$350,000 | |
| Original award | $350,000 |
Show all 24
Subawards
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Quick answers
Who was awarded contract 75N91019D00024?
75N91019D00024 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on June 26, 2019.
How much is contract 75N91019D00024 worth?
Orders under 75N91019D00024 have obligated $6,803,449,351. Their combined current value, with exercised options, is $6,937,961,021. Their combined potential value, with all options, is $7,126,473,169. 75N91019D00024's own ceiling is $10,916,000,000.
How many orders have been placed under contract 75N91019D00024?
185 orders have been placed under 75N91019D00024, the latest on September 30, 2026.
Who can order from contract 75N91019D00024?
75N91019D00024 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N91019D00024 competed?
The extent of competition for 75N91019D00024 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV